文献速递临床微生物质量管理与危急值

公共卫生外展可促进现行药敏折点采纳,但监管机构需更密切关注

Public Health Efforts Can Impact Adoption of Current Susceptibility Breakpoints, but Closer Attention from Regulatory Bodies Is Needed.
PubMed 文献 · J Clin Microbiol · 2019-02-27

洛杉矶县公共卫生部对41家使用过时肠杆菌科碳青霉烯类折点的医院开展为期1年的外展干预,通过访谈和定制指导帮助更新折点。干预后16家(47%)成功更新,12家(35%)获得CDC菌株用于验证,6家(18%)计划1年内更新,但多数目标医院仍使用过时折点。

要点

  • 使用过时肠杆菌科碳青霉烯类折点影响患者安全与感染控制。
  • 外展干预后仅47%目标医院成功更新折点。
  • 多数医院误以为仪器已应用现行折点,且缺乏验证资源。

核心结论

  • 公共卫生干预在识别和克服更新肠杆菌科碳青霉烯类折点的障碍方面取得中等成功,但多数目标医院在1年努力后仍使用过时折点。

研究设计与样本

  • 洛杉矶县公共卫生部对41家曾报告使用过时肠杆菌科碳青霉烯类折点的医院开展为期1年的外展项目,提供面对面访谈、定制专家指导及资源支持。

主要发现

  • 41家目标医院中7家在此前调查后已更新折点;剩余34家中27家(79%)假设仪器已应用现行折点,17家(50%)不确定如何更改折点,10家(29%)缺乏资源进行验证研究。
  • 仅7家医院(21%)熟悉FDA/CDC抗生素耐药菌株库。
  • 所有医院启动折点更新流程,16家(47%)成功更新,12家(35%)获得CDC菌株用于验证,6家(18%)计划1年内更新。

临床怎么用

  • 检验科应主动核实仪器所用折点是否为现行版本,避免因假设而沿用过期折点。
  • 更新折点时需评估验证研究资源,可借助监管机构或菌株库支持。

局限性

  • 干预仅覆盖洛杉矶县41家医院,外推性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Microbiological testing, including interpretation of antimicrobial susceptibility testing results using current breakpoints, is crucial for clinical care and infection control. Continued use of obsolete Enterobacteriaceae carbapenem breakpoints is common in clinical laboratories. The purposes of this study were (i) to determine why laboratories failed to update breakpoints and (ii) to provide support for breakpoint updates. The Los Angeles County Department of Public Health conducted a 1-year outreach program for 41 hospitals in Los Angeles County that had reported, in a prior survey of California laboratories, using obsolete Enterobacteriaceae carbapenem breakpoints. In-person interviews with hospital stakeholders and customized expert guidance and resources were provided to aid laboratories in updating breakpoints, including support from technical representatives from antimicrobial susceptibility testing device manufacturers. Forty-one hospitals were targeted, 7 of which had updated breakpoints since the prior survey. Of the 34 remaining hospitals, 27 (79%) assumed that their instruments applied current breakpoints, 17 (50%) were uncertain how to change breakpoints, and 10 (29%) lacked resources to perform a validation study for off-label use of the breakpoints on their systems. Only 7 hospitals (21%) were familiar with the FDA/CDC Antibiotic Resistance Isolate Bank. All hospitals launched a breakpoint update process; 16 (47%) successfully updated breakpoints, 12 (35%) received isolates from the CDC in order to validate breakpoints on their systems, and 6 (18%) were planning to update within 1 year. The public health intervention was moderately successful in identifying and overcoming barriers to updating Enterobacteriaceae carbapenem breakpoints in Los Angeles hospitals. However, the majority of targeted hospitals continued to use obsolete breakpoints despite 1 year of effort. These findings have important implications for the quality of patient care and patient safety. Other public health jurisdictions may want to utilize similar resources to bridge the patient safety gap, while manufacturers, the FDA, and others determine how best to address this growing public health issue.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. McKinnell JA, Bhaurla S, Marquez-Sung P, et al. Public Health Efforts Can Impact Adoption of Current Susceptibility Breakpoints, but Closer Attention from Regulatory Bodies Is Needed. J Clin Microbiol. 2019. PMID: 30567751. doi:10.1128/JCM.01488-18

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。